Is it effectively balanced between technology, people, and partnerships to accelerate drug pipelines?
(A Frost & Sullivan Webinar)

The Pharmaceutical Research and Development Lab of the Future is Here

Have you prioritized the best emerging technologies to transform therapeutic development? Will the connected lab drive scientific innovation? What role should AI and the internet-of-things play to revolutionize pharmaceutical R&D? How will your talent need to evolve?

There were already profound changes taking place in life sciences R&D and the pandemic forced business and suppliers to adapt at an even more accelerated pace. Research, driven by technological advances and the continued path towards developing precision medicines is changing the concept of what the lab is.

As life science executives face new challenges, they are focused on transformational initiatives to outsource, automate, and integrate game changing technologies while applying innovative thinking to their Lab of the Future design. Finding the right partner to help create an ideal environment for scientists to innovate and collaborate internally and externally will be key to deliver the best possible treatments to patients faster and cost effectively.

Key learning objectives:

  • Learn about strategies that pharmaceutical industry leaders are applying to accelerate their pipeline
  • Explore emerging technologies to address capability gaps for next-generation therapeutics
  • Discover innovations that ensure seamless integration of Lab instruments and IT infrastructure
  • Assess opportunities to rethink leveraging the combination of automation, the cloud, augmented reality, and outsourcing
  • See trends where strategic partners are resolving R&D challenges
  • Hear how executives are applying new thinking into the R&D lab that fosters creativity and innovation to accelerate discovery and development of new medicines

Who should attend:

  • Multi-national R&D science leaders and procurement in pharma/biopharma/biotech companies, who are committed to accelerating their strategic direction through their own research or through outsourcing to contract research analytical testing or development
  • International biopharma and pharmaceutical industry players striving to improve scale and reach while balancing the cost of research with a focus on drug discovery and drug marketing
  • Contract research organization leaders focused on partnership in drug discovery and development with pharma/biopharma/biotech organizations
  • Executives in contract research organizations that play a key role on a contract basis to provide comprehensive services and scale from drug development through drug manufacturing, where their clients wish to outsource those aspects of the business so they can focus on drug discovery and drug marketing instead

About the presenters

Dennis Kimmel, PharmD, MBA, Senior Consultant, Transformational Health, Americas, Frost & Sullivan

Dennis Kimmel, PharmD, MBA, Senior Consultant, Transformational Health, Americas, Frost & Sullivan

Christopher Yu, Director, Genentech

Christopher Yu, Director, Genentech

Inguva Sivaram, Global Lead Data and Digital, ARD, Novartis

Inguva Sivaram, Global Lead Data and Digital, ARD, Novartis

Andreas Huhmer, PhD, Sr. Director, Global Vertical Marketing, Thermo Fisher Scientific

Andreas Huhmer, PhD, Sr. Director, Global Vertical Marketing, Thermo Fisher Scientific

Dr. Beate Hanson, Sr. Medical Director, Worldwide, Medical, Clinical Research, Baxter International, Inc.

Dr. Beate Hanson, Sr. Medical Director, Worldwide, Medical, Clinical Research, Baxter International, Inc.

Priya Mannan, Sr. Director, Global Head of Compliance, Data Privacy and Associate General Counsel, Novartis

Priya Mannan, Sr. Director, Global Head of Compliance, Data Privacy and Associate General Counsel, Novartis

Overview

Have you prioritized the best emerging technologies to transform therapeutic development? Will the connected lab drive scientific innovation? What role should AI and the internet-of-things play to revolutionize pharmaceutical R&D? How will your talent need to evolve?

There were already profound changes taking place in life sciences R&D and the pandemic forced business and suppliers to adapt at an even more accelerated pace. Research, driven by technological advances and the continued path towards developing precision medicines is changing the concept of what the lab is.

As life science executives face new challenges, they are focused on transformational initiatives to outsource, automate, and integrate game changing technologies while applying innovative thinking to their Lab of the Future design. Finding the right partner to help create an ideal environment for scientists to innovate and collaborate internally and externally will be key to deliver the best possible treatments to patients faster and cost effectively.

Learning

Key learning objectives:

  • Learn about strategies that pharmaceutical industry leaders are applying to accelerate their pipeline
  • Explore emerging technologies to address capability gaps for next-generation therapeutics
  • Discover innovations that ensure seamless integration of Lab instruments and IT infrastructure
  • Assess opportunities to rethink leveraging the combination of automation, the cloud, augmented reality, and outsourcing
  • See trends where strategic partners are resolving R&D challenges
  • Hear how executives are applying new thinking into the R&D lab that fosters creativity and innovation to accelerate discovery and development of new medicines
Attendance

Who should attend:

  • Multi-national R&D science leaders and procurement in pharma/biopharma/biotech companies, who are committed to accelerating their strategic direction through their own research or through outsourcing to contract research analytical testing or development
  • International biopharma and pharmaceutical industry players striving to improve scale and reach while balancing the cost of research with a focus on drug discovery and drug marketing
  • Contract research organization leaders focused on partnership in drug discovery and development with pharma/biopharma/biotech organizations
  • Executives in contract research organizations that play a key role on a contract basis to provide comprehensive services and scale from drug development through drug manufacturing, where their clients wish to outsource those aspects of the business so they can focus on drug discovery and drug marketing instead
Speakers

About the presenters

Dennis Kimmel, PharmD, MBA, Senior Consultant, Transformational Health, Americas, Frost & Sullivan

Dennis Kimmel, PharmD, MBA, Senior Consultant, Transformational Health, Americas, Frost & Sullivan

Christopher Yu, Director, Genentech

Christopher Yu, Director, Genentech

Inguva Sivaram, Global Lead Data and Digital, ARD, Novartis

Inguva Sivaram, Global Lead Data and Digital, ARD, Novartis

Andreas Huhmer, PhD, Sr. Director, Global Vertical Marketing, Thermo Fisher Scientific

Andreas Huhmer, PhD, Sr. Director, Global Vertical Marketing, Thermo Fisher Scientific

Dr. Beate Hanson, Sr. Medical Director, Worldwide, Medical, Clinical Research, Baxter International, Inc.

Dr. Beate Hanson, Sr. Medical Director, Worldwide, Medical, Clinical Research, Baxter International, Inc.

Priya Mannan, Sr. Director, Global Head of Compliance, Data Privacy and Associate General Counsel, Novartis

Priya Mannan, Sr. Director, Global Head of Compliance, Data Privacy and Associate General Counsel, Novartis

Register to view the free
on-demand webinar

* Required field

*
*
*
*
*
*
 
*
*
*
 I would like to speak with an sales representative to learn how Thermo Fisher Scientific products can help in my laboratory
 Please confirm you would like to receive marketing and promotional email messages about Thermo Fisher Scientific products and services.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.